ARA-290 vs Oxytocin
Side-by-side comparison of key properties, dosing, and research.
- Summary
- ARA-290 is a synthetic 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, it selectively activates the innate repair receptor (IRR) without stimulating hematopoiesis, providing tissue protection, anti-inflammation, and neuropathy relief.
- Oxytocin is a 9-amino acid neuropeptide produced in the hypothalamus with diverse roles in social bonding, trust, stress reduction, and sexual function. Exogenous administration is used therapeutically to improve social cognition, reduce anxiety, and enhance intimacy.
- Half-Life
- ~2–4 hours (SC administration)
- ~3–5 minutes (IV); ~30–60 minutes (intranasal, CNS effects persist longer)
- Admin Route
- SubQ
- Intranasal, SubQ, IV
- Research
- —
- —
- Typical Dose
- 4 mg (fixed dose)
- 20–40 IU
- Frequency
- Once daily
- As needed (not daily long-term)
- Key Benefits
- Reduces neuropathic pain from small fiber neuropathy
- Anti-inflammatory without immune suppression
- Tissue protection after ischemia/reperfusion injury
- Promotes nerve fiber regeneration
- Improves symptoms of sarcoidosis-associated neuropathy
- May reduce insulin resistance and improve metabolic health
- Shown to improve autonomic neuropathy symptoms
- Enhances social bonding and trust
- Reduces social anxiety and fear of rejection
- Improves autism spectrum symptoms (social cognition)
- Reduces cortisol and stress reactivity
- Enhances sexual arousal and intimacy
- Promotes maternal behavior and bonding
- May improve depressive symptoms
- Appetite suppression and metabolic effects
- Side Effects
- Injection site reactions
- Mild fatigue at initiation
- Transient warm sensation post-injection
- Rare: mild headache
- Mild uterine cramping (avoid in pregnancy)
- Nasal irritation (intranasal)
- Headache
- Potential emotional over-attachment or jealousy amplification
- +2 more
- Stacks With
- —
- —